Anuh Pharma is an API manufacturer based in India. It holds 3 valid CEPs across a filed portfolio of 4 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 6 February 2026 as NAI. Customs aggregates show $42.1M of exports covering 957 molecules to 78 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Mumbai, India | Not on file |
| Thane, India | 3001174909 |
| Boisar, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Betamethasone | SFDA (Saudi Arabia) | 1 |
| Pyrazinamide | EDQM | 1 |
| Sulfadimethoxine | EDQM | 1 |
| Sulfadoxine | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 5 | None |
| US FDA | None | 1 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $5.1M | 38 |
| 2025 | Not reported | $42.1M | 78 |
| 2024 | Not reported | $28.0M | 69 |
| 2023 | Not reported | $30.2M | 65 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Anuh Pharma comes back tiered against every other supplier able to file there.
Start for free